&nbsp;

Aug 2024

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Sep 2024

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Nov 2024

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

IRIN+CETU; IRIN(Q2W)+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

cetuximab,

irinotecan

Quick Link(s):

Regimen Monograph

Jun 2022

Regimen

IPIL

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Ipilimumab - Previously Untreated Advanced Unresectable Melanoma

New Drug Funding Program

Ipilimumab - Previously Treated Advanced Unresectable Melanoma

Drugs Used:

ipilimumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

BEND

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Chronic Lymphocytic Leukemia

Drugs Used:

bendamustine

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BEND+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

New Drug Funding Program

Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Nov 2024

Regimen

BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell

Intent: Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Systemic Anaplastic Large Cell Lymphoma

Drugs Used:

brentuximab vedotin

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen

BREN

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma

Drugs Used:

brentuximab vedotin